• Overview
  • Details
  • More
Share Products Categories Channel Cart
1/6
Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib图1Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib图2Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib图3Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib图4Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib图5Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib图6

Tooth Regeneration Tideglusib Pharmaceutical Grade Tideglusib Powder Raw Material Tideglusib

Price $100.00
Min Order 1 g  
Shipping from Shaanxi, China
Quantity
-+
Product details
D-sung-Tideglusib
865854-05-3
C19h14n2o2s
N/M
Pharmaceutical Intermediates
Powder
Tideglusib
White
Tideglusib
Tideglusib Powder
White Powder
148-150oc
511.3oc at 760 Mmhg
1.735
1.393
Pharmaceutical Grade
Pharmaceutical
99%
COA
C19h14n2o2s
HPLC UV
2 Years
334.39
D-sung
Negotiable
99%
Shaanxi
Product Description
Tooth Regeneration Tideglusib Pharmaceutical grade Tideglusib powder Raw material Tideglusib
Product Description

 

Product NameTideglusib
CAS NO.865854-05-3
Purity99%
Melting point148-150 C
Appearance and shapeWhite powder
Tideglusib (NP-12, NP031112) is a potent, selective and irreversible small molecule non-ATP-competitive glycogen synthase kinase 3 (GSK-3) inhibitor.. Other GSK inhibitors. There are few classes of GSK-inhibitors, including lithium (Martinez et al., 2011), the small peptide L803mts10, and members of the thiazolidinedione family, containing non-competitive inhibitors of GSK-3, such as TDZD-8.Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer disease and progressive supranuclear palsy.
Application&Function

Tideglusib was originally developed to treat Alzheimer's disease, but it was unexpectedly discovered that it can be used to regenerate damaged teeth. Tideglusib is an irreversible, non-ATP-competitive GSK-3β inhibitor with IC50 of 60 nM.On November 9, 2020, AMO pharma announced that the FDA has granted its investigational therapy AMO-02 (tideglusib) Rare Pediatric Disease (RPD) designation for the treatment of congenital myotonic dystrophy.

Specification

Certifications

Packaging & Shipping

Buyer review
Loading review details...
Contact

Xi`an Disheng Health Biotechnology Co., Ltd.

Audited Supplier4 Years
ProfileCertified by SGS/BV

Message Type

* Content

* Name

* Phone

* Email

* Captcha

captcha

Recommended for you